Form 990 for tax year 2024
Filed by T A G TREATMENT ACTION GROUP INC.
Totals
- Total revenue
- $3,574,921
- Total expenses
- $4,092,642
- Contributions and grants received
- $3,477,949
- Grants paid
- $686,417
- Program service revenue
- $29,185
- Investment income
- $63,987
- Other revenue
- $3,800
- Total assets, end of year
- $3,839,139
- Total liabilities, end of year
- $745,777
- Net assets or fund balances, end of year
- $3,093,362
- Program services expenses (Part IX)
- $3,377,153
- Management and general expenses
- $419,692
- Fundraising expenses
- $295,797
- Program service expenses (Part III)
- $3,377,153
Program services were 82.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$188,342
-
1e · Government grants (contributions)
$78,093
-
1f · All other contributions, gifts and grants
$3,211,514
-
2a · Program service revenue: OTHER PROGRAM INCOME
total $29,185 · related or exempt $29,185
-
3 · Investment income
total $63,987 · excluded $63,987
-
8a · Fundraising events: gross income
$45,020
-
8a · Fundraising events: contributions included on line 1c
$188,342
-
8b · Fundraising events: direct expenses
$45,020
-
8c · Net income from fundraising events
total $0
-
10a · Gross sales of inventory
$3,800
-
10b · Cost of goods sold
$0
-
10c · Net income from sales of inventory
total $3,800 · excluded $3,800
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $8,308 · program services $8,308
-
3 · Grants to foreign organizations and individuals
total $678,109 · program services $678,109
-
5 · Compensation of officers, directors and key employees
total $360,178 · program services $213,809 · management and general $80,228 · fundraising $66,141
-
7 · Other salaries and wages
total $1,528,923 · program services $1,269,800 · management and general $187,683 · fundraising $71,440
-
9 · Other employee benefits
total $426,513 · program services $345,300 · management and general $55,295 · fundraising $25,918
-
10 · Payroll taxes
total $135,596 · program services $107,096 · management and general $18,926 · fundraising $9,574
-
11d · Fees: lobbying
total $7,554 · management and general $7,554
-
11g · Fees: other
total $302,856 · program services $267,403 · management and general $21,404 · fundraising $14,049
-
12 · Advertising and promotion
total $1,578 · program services $355 · management and general $125 · fundraising $1,098
-
13 · Office expenses
total $32,084 · program services $17,081 · management and general $4,152 · fundraising $10,851
-
14 · Information technology
total $40,302 · program services $32,528 · management and general $4,728 · fundraising $3,046
-
16 · Occupancy
total $158,874 · program services $119,702 · management and general $26,250 · fundraising $12,922
-
17 · Travel
total $215,651 · program services $199,802 · management and general $4,595 · fundraising $11,254
-
19 · Conferences, conventions and meetings
total $31,576 · program services $30,700 · fundraising $876
-
22 · Depreciation, depletion and amortization
total $5,000 · program services $3,767 · management and general $826 · fundraising $407
-
23 · Insurance
total $24,225 · program services $18,252 · management and general $4,003 · fundraising $1,970
-
24a · Other expenses: FUNDRAISING EVENTS
total $53,081 · fundraising $53,081
-
24b · Other expenses: PRINTING & PUBLICATIONS
total $44,850 · program services $39,142 · management and general $421 · fundraising $5,287
-
24c · Other expenses: DUES AND SUBSCRIPTIONS
total $23,086 · program services $21,871 · management and general $1,130 · fundraising $85
-
24d · Other expenses: MISCELLANEOUS
total $7,179 · program services $4,128 · management and general $2,327 · fundraising $724
-
24e · All other expenses
total $7,119 · management and general $45 · fundraising $7,074
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $48,553 · end of year $44,940
-
2 · Savings and temporary cash investments
beginning of year $1,394,085 · end of year $1,346,271
-
3 · Pledges and grants receivable
beginning of year $1,796,031 · end of year $1,191,129
-
4 · Accounts receivable
beginning of year $8,271
-
9 · Prepaid expenses and deferred charges
beginning of year $72,871 · end of year $76,668
-
10a · Land, buildings and equipment: cost or other basis
$103,743
-
10b · Land, buildings and equipment: accumulated depreciation
$89,961
-
10c · Land, buildings and equipment, net
beginning of year $13,565 · end of year $13,782
-
15 · Other assets
beginning of year $1,290,656 · end of year $1,166,349
-
17 · Accounts payable and accrued expenses
beginning of year $74,007 · end of year $72,148
-
25 · Other liabilities
beginning of year $938,942 · end of year $673,629
-
27 · Net assets without donor restrictions
beginning of year $1,775,039 · end of year $1,483,863
-
28 · Net assets with donor restrictions
beginning of year $1,836,044 · end of year $1,609,499
Mission and programs · 2024
Mission
TREATMENT ACTION GROUP (TAG) IS AN INDEPENDENT, ACTIVIST, AND COMMUNITY-BASED RESEARCH AND POLICY THINK TANK COMMITTED TO RACIAL, GENDER, AND LGBTQ+ EQUITY; SOCIAL JUSTICE; AND LIBERATION, FIGHTING TO END HIV, TUBERCULOSIS (TB), AND HEPATITIS C VIRUS (HCV).TAG CATALYZES OPEN COLLECTIVE ACTION BY AFFECTED COMMUNITIES, SCIENTISTS, AND POLICYMAKERS TO ENSURE THAT ALL PEOPLE LIVING WITH OR IMPACTED BY HIV, TB, OR HCV - ESPECIALLY COMMUNITIES OF COLOR AND OTHER MARGINALIZED COMMUNITIES EXPERIENCING INEQUITIES - RECEIVE LIFE-SAVING PREVENTION, DIAGNOSIS, TREATMENT, CARE, AND INFORMATION.WE ARE SCIENCE-BASED ACTIVISTS WORKING TO EXPAND AND ACCELERATE VITAL RESEARCH AND EFFECTIVE COMMUNITY ENGAGEMENT WITH RESEARCH AND POLICY INSTITUTIONS FOR AN END TO THE HIV, TB, AND HCV PANDEMICS.
-
SEE SCHEDULE OTUBERCULOSIS (TB) PROGRAMACCORDING TO THE LATEST REPORT FROM THE WORLD HEALTH ORGANIZATION (WHO), IN 2023, TB PROBABLY RETURNED TO BEING THE WORLD'S LEADING CAUSE OF DEATH FROM A SINGLE INFECTIOUS AGENT, FOLLOWING 3 YEARS IN WHICH IT WAS REPLACED BY CORONAVIRUS DISEASE (COVID-19), AND CAUSED ALMOST TWICE AS MANY DEATHS AS HIV/AIDS. MORE THAN 10 MILLION PEOPLE CONTINUE TO FALL ILL WITH TB EVERY YEAR AND THE NUMBER HAS BEEN RISING SINCE 2021. URGENT ACTION IS REQUIRED TO END THE GLOBAL TB EPIDEMIC BY 2030, A GOAL THAT HAS BEEN ADOPTED BY ALL MEMBER STATES OF THE UNITED NATIONS (UN) AND THE WORLD HEALTH ORGANIZATION (WHO)." RECOGNIZING THAT MUCH MORE PROGRESS COULD BE MADE IF EXISTING TOOLS WERE FULLY IMPLEMENTED, AND THAT MORE RESEARCH IS NEEDED TO END TB, TAG'S TB PROGRAM STRENGTHENS EVIDENCE-DRIVEN AND HUMAN RIGHTS-BASED ADVOCACY BOTH FOR BETTER TB RESEARCH, AND FOR HIGH-QUALITY PROGRAMS AND POLICIES WORLDWIDE, THAT MEET THE NEEDS OF AFFECTED COMMUNITIES.TAG'S TB PROGRAM EDUCATES, MOBILIZES, AND EMPOWERS COMMUNITIES TO INCREASE UNDERSTANDING OF TB AND TO CATALYZE ACTION TO REDUCE NEW INFECTIONS, DEATHS, AND SUFFERING FROM TB AND TB/HIV. THE PROGRAM WORKS WITH COMMUNITY ADVOCATES, COMMUNITY ADVISORY BOARDS, RESEARCHERS, POLICY MAKERS, DEVELOPERS, AND DONORS TO ENSURE NEEDS-DRIVEN RESEARCH TO IMPROVE OPTIONS FOR TB PREVENTION, DIAGNOSIS, AND TREATMENT. THE TB PROGRAM PUBLISHES AN ANNUAL REPORT ON TB RESEARCH FUNDING TRENDS, AND ADVOCATES FOR ALL GOVERNMENTS OF THE WORLD TO STEP UP AND CONTRIBUTE THEIR "FAIR SHARE" INVESTMENTS IN TB R&D.THE TB PROGRAM WORKS WITH RESEARCHERS, ACTIVISTS, AND POLICYMAKERS AROUND THE WORLD TO ENSURE TRANSPARENCY AND UNIVERSAL, EQUITABLE, AFFORDABLE ACCESS TO PROVEN INTERVENTIONS, FROM EARLY IN THE RESEARCH PROCESS THROUGH REGULATORY APPROVAL TO GLOBAL AND NATIONAL GUIDELINES DEVELOPMENT AND PRODUCT PRICING. TAG'S POLICY TEAM SUPPORTS THE TB PROGRAM IN EDUCATING U.S. LEGISLATORS AND OFFICIALS ON TB PRIORITIES, AND LEADS DOMESTIC WORK AT THE LOCAL, STATE, AND NATIONAL LEVEL TO SUPPORT AMBITIOUS AND EVIDENCE-BASED PROGRAMMING TO END.
Expenses $2,150,585 · Grants $654,930 · Revenue $29,185
-
SEE SCHEDULE OHIV PROGRAMACCORDING TO THE JULY 2025 UNAIDS GLOBAL AIDS REPORT, "40.8 MILLION [37.0 MILLION-45.6 MILLION] PEOPLE GLOBALLY WERE LIVING WITH HIV IN 2024. 1.3 MILLION [1 MILLION-1.7 MILLION] PEOPLE BECAME NEWLY INFECTED WITH HIV IN 2024. 630 000 [490 000-820 000] PEOPLE DIED FROM AIDS-RELATED ILLNESSES IN 2024. 31.6 MILLION PEOPLE [27.8-32.9 MILLION] WERE ACCESSING ANTIRETROVIRAL THERAPY IN 2024. 91.4 MILLION [73.4 MILLION-116.4 MILLION] PEOPLE HAVE BECOME INFECTED WITH HIV SINCE THE START OF THE EPIDEMIC. 44.1 MILLION [37.6 MILLION-53.4 MILLION] PEOPLE HAVE DIED FROM AIDS-RELATED ILLNESSES SINCE THE START OF THE EPIDEMIC." ACCORDING TO THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) 2025 UPDATE, THERE WERE OVER 39,000 PEOPLE NEWLY DIAGNOSED WITH HIV, ALMOST 4,500 HIV-RELATED DEATHS, AND OVER 1,132,000 AMERICANS LIVING WITH HIV BY THE END OF 2023.TAG'S HIV PROGRAM WORKS TO MAXIMIZE EQUITABLE, AFFORDABLE ACCESS TO THE TOOLS, SERVICES, POLICIES, AND APPROACHES TO PREVENTION AND CARE THAT ARE ESSENTIAL FOR THE GOAL OF ENDING THE HIV EPIDEMIC DOMESTICALLY AND GLOBALLY. ADVOCACY FOCUSED ON ENDING THE EPIDEMIC (ETE, OR EHE) IS AT THE CORE OF THE HIV PROGRAM'S WORK, FROM DRIVING THE NATION'S FIRST ETE INITIATIVE IN NEW YORK TO LEADING THE ACT NOW: END AIDS (ANEA) COALITION'S SUPPORT FOR PARTNERS IN HEAVILY BURDENED JURISDICTIONS IN THE SOUTHERN U.S. TAG'S HIV AND POLICY TEAMS TACKLE ISSUES AROUND DRUG PRICING AND EQUITABLE ACCESS TO EMERGING BIOMEDICAL INTERVENTIONS; FUNDING FOR EVIDENCE-BASED HIV PROGRAMMING; ACCESS TO HEALTHCARE; AND POLICIES THAT PROMOTE SAFE, INCLUSIVE ENVIRONMENTS THAT ARE FREE OF STIGMA AND DISCRIMINATION FOR PEOPLE TO SEEK PREVENTION AND CARE FOR HIV AND RELATED INFECTIONS, INCLUDING SEXUALLY TRANSMITTED INFECTIONS.TAG'S HIV PROGRAM LEADS RESEARCH ACTIVISM AND PROMOTES COMMUNITY ENGAGEMENT TO ENSURE THAT PEOPLE LIVING WITH HIV EVERYWHERE HAVE MORE OPTIONS INCLUDING, ULTIMATELY, A SAFE AND EFFECTIVE HIV VACCINE AND A CURE THAT ARE SCALABLE, AFFORDABLE, AND CAN BE USED WORLDWIDE. TAG'S HIV PROGRAM RECOGNIZES THAT EVEN THE MOST EFFECTIVE EXISTING PREVENTION AND TREATMENT INTERVENTIONS HAVE SHORTCOMINGS. TO THIS END, TAG'S BASIC SCIENCE, VACCINE AND CURE PROJECT TRACKS THE ANTIRETROVIRAL, CURE, IMMUNE-BASED THERAPY, AND BIOMEDICAL PREVENTION PIPELINES AND PUBLISHES ANNUAL REPORTS SUMMARIZING THEIR CURRENT STATUS. TAG ALSO PLAYS A VITAL LEADERSHIP ROLE IN BASIC SCIENCE, VACCINES, AND CURE ADVOCACY, PARTICIPATING IN COMMUNITY ADVISORY BOARDS AND ADMINISTERING AN EMAIL DISCUSSION LISTSERV FOR STAKEHOLDERS IN HIV CURE AND IMMUNE-BASED THERAPY RESEARCH. IN 2024, TAG CONTRIBUTED TO THE NEW U.S. NATIONAL INSTITUTES OF HEALTH (NIH) STRATEGIC PLAN FOR HIV AND HIV-RELATED RESEARCH, COVERING 2026-2030. DURING THE PLANNING PROCESS, TAG'S HIV PROJECT STAFF SERVED ON THE NIH OFFICE OF AIDS RESEARCH BASIC BIOMEDICAL AND PRECLINICAL RESEARCH TASKFORCE. TAG'S HIV CURE-RELATED CLINICAL TRIALS WEBSITE LISTING, UPDATED MONTHLY TO PROVIDE INFORMATION ON STUDIES AND THEIR RESULTS, IS WIDELY CITED IN SCIENTIFIC PAPERS AND IN CONFERENCE PRESENTATIONS. THE HIV PROGRAM ALSO ADVOCATES FOR APPROPRIATE INTERVENTIONS FOR PEOPLE WHO, DESPITE HIV TREATMENT, STILL HAVE POOR IMMUNE SYSTEM RECOVERY. CENTRAL TO THIS WORK IS ENSURING LEGISLATORS AND POLICY MAKERS UNDERSTAND THE ONGOING NEEDS FOR RESEARCH AND HIV-RELATED FUNDING, AND HOW IMPORTANT IT IS TO MAKE DECISIONS BASED ON SCIENTIFIC EVIDENCE.TAG STAFF CONTINUE TO PARTICIPATE AS MEMBERS OF THE PREP IN BLACK AMERICA COALITION, A NETWORK OF ADVOCATES WORKING TO INCREASE EQUITABLE ACCESS AND UPTAKE OF PRE-EXPOSURE PROPHYLAXIS FOR HIV PREVENTION, WHICH IN APRIL 2024 HOSTED A RESEARCH-FOCUSED PRE-CONFERENCE AHEAD OF THE NMAC BIOMEDICAL HIV PREVENTION SUMMIT. TAG ALSO CONTINUES TO LEAD AND CO-ORGANIZE COMMUNITY ENGAGEMENT ACTIVITIES ON HIV CURE RESEARCH, INCLUDING THE ANNUAL PRE-CROI COMMUNITY HIV CURE RESEARCH WORKSHOP, AND CONTINUES TO MAINTAIN THE ONLY KNOWN DATABASE MONITORING THE DEMOGRAPHICS OF PARTICIPANTS IN HIV CURE-FOCUSED CLINICAL TRIALS. ALL WEBINARS AND MATERIALS PRODUCED BY THE HIV PROGRAM ARE AVAILABLE ON TAG'S WEBSITE.IN 2024, TAG'S HIV PROGRAM CONDUCTED COMMUNITY ENGAGEMENT ACTIVITIES ON THE TOPICS OF BIOMEDICAL HIV PREVENTION, ENHANCING PRIOR AND CURRENT PROGRAMMING THROUGH SEVERAL WEBINARS FOCUSED ON TOPICS SUCH IMPLEMENTATION OF LONG-ACTING INJECTABLE HIV TREATMENT AND PREVENTION, AS WELL AS COVERING HIV AWARENESS, SEXUAL AND REPRODUCTIVE HEALTH AMONG YOUNG PEOPLE. EDUCATION AND HEALTH PROMOTION WAS ALSO ENHANCED BY TAG'S SOCIAL MEDIA AMBASSADORSHIP PROGRAM IN COLLABORATION WITH THE HIV VACCINE TRIALS NETWORK, AND SOUTHERN AIDS COALITION, COLLABORATION WITH THE PREP IN BLACK AMERICA COALITION; AND INCLUDING REAL-TIME COVERAGE OF SEVERAL IMPORTANT CONFERENCES, MEETINGS AND EVENTS ATTENDED BY HEAVILY AFFECTED COMMUNITIES, SUCH AS THE HIV VACCINE TRIALS NETWORK (HVTN) FULL GROUP MEETING, THE AIDS WALK NY, THE NATIVE SON AWARDS, THE SAVING OURSELVES SYMPOSIUM HOSTED BY SOUTHERN AIDS COALITION, AND THE U.S. CONFERENCE ON HIV AND AIDS, AMONG OTHERS. THE TAG HIV PROGRAM CULMINATED WITH A WORLD AIDS DAY TOWN HALL FORUM CO-HOSTED BY TAG IN COLLABORATION WITH SIRIUSXM. SINCE 2024, THE ACT NOW: END AIDS (ANEA) COALITION HAS CONTINUED TO ACHIEVE SIGNIFICANT MILESTONES IN ITS MISSION TO COMBAT HIV/AIDS AND PROMOTE EQUITABLE ACCESS TO CARE, THROUGH STRATEGIC CONVENINGS, POLICY ENGAGEMENT, AND KNOWLEDGE-BUILDING INITIATIVES. IN 2024, ANEA HOSTED REGULAR COALITION MEETINGS TO ALIGN EFFORTS ACROSS THE SOUTH AND NATIONALLY, AND HELD A CONGRESSIONAL BRIEFING ON THE ENDING THE HIV EPIDEMIC (EHE) INITIATIVE TO UPLIFT THE VOICES AND PRIORITIES OF PEOPLE LIVING WITH HIV. WE PARTNERED WITH THE TEXAS STRIKE FORCE TO DELIVER A WEBINAR HIGHLIGHTING GRASSROOTS STRATEGIES FOR STATE-LEVEL ADVOCACY, AND DESIGNED MULTIPLE WORKSHOPS AT USCHA 2024, WHICH CULMINATED IN A PUBLISHED PAPER CENTERING BLACK WOMEN'S BODILY AUTONOMY IN THE CONTEXT OF HIV ADVOCACY. ADDITIONALLY, ANEA BEGAN WORKING WITH A PUBLICATION DESIGN CONSULTANT TO ADVANCE THE PRODUCTION OF A COMPREHENSIVE EHE READINESS ASSESSMENT IN COLLABORATION WITH PARTNER JURISDICTIONS, CONSISTING OF A DETAILED SURVEY AND KEY INFORMANT INTERVIEWS. THIS ASSESSMENT WILL PROVIDE KEY UNDERSTANDING OF THE SUCCESSES AND CHALLENGES ENCOUNTERED IN UTILIZING EHE FUNDS TO REACH HIGHLY-IMPACTED COMMUNITIES. THROUGH THESE EFFORTS, ANEA CONTINUES TO FOSTER LEADERSHIP, STRENGTHEN PARTNERSHIPS, AND ADVANCE POLICY ROOTED IN LIVED EXPERIENCE.
Expenses $906,992 · Grants $8,308
-
SEE SCHEDULE OHEPATITIS C VIRUS (HCV) PROGRAMACCORDING TO THE WORLD HEALTH ORGANIZATION'S GLOBAL HEPATITIS REPORT 2024, OF THE 50 MILLION PEOPLE ESTIMATED TO BE LIVING WITH CHRONIC HEPATITIS C VIRUS INFECTION, ONLY 36% WERE DIAGNOSED BETWEEN 2015 AND 2022, AND 20% RECEIVED TREATMENT. IN 2022 ALONE, ABOUT 1 MILLION NEW HCV INFECTIONS AND APPROXIMATELY 221 000 HCV-RELATED DEATHS WERE REGISTERED, MOSTLY FROM CIRRHOSIS AND HEPATOCELLULAR CARCINOMA.[1] ABOUT 2.3 MILLION PEOPLE (6.2%) OF THE ESTIMATED 37.7 MILLION LIVING WITH HIV GLOBALLY IN 2020 HAD SEROLOGICAL EVIDENCE OF PAST OR PRESENT HCV INFECTION.TAG'S HCV PROGRAM HAS BEEN AT THE FOREFRONT OF A GLOBAL HCV EDUCATION AND ADVOCACY MOVEMENT, WORKING IN COLLABORATION WITH AFFECTED COMMUNITIES, SCIENTISTS, GOVERNMENTS, AND DRUG COMPANIES TO MAKE LIFE-SAVING INFORMATION, HIGH QUALITY AND AFFORDABLE TESTING AND CURES, AND ENSURING A SUPPORTIVE ENVIRONMENT FOR UNDERSERVED POPULATIONS UNIVERSALLY. THIS INCLUDES TRACKING THE PIPELINE FOR HCV INNOVATIONS, INCLUDING THE LATEST PANGENOTYPIC TREATMENTS, DIAGNOSTICS, AND LONG-ACTING INJECTABLES, AND INCREASING COMMUNITIES' DIAGNOSTICS AND TREATMENT LITERACY. GLOBALLY, TAG PROVIDES TECHNICAL ASSISTANCE TO BUILD LEADERSHIP CAPACITY FOR ADVANCING NATIONAL ELIMINATION CAMPAIGNS AND AMPLIFYING COMMUNITY VOICES-ESPECIALLY THOSE OF KEY POPULATIONS SUCH AS PEOPLE WHO USE DRUGS, SEX WORKERS, PEOPLE IN INCARCERATION, MIGRANTS, AND MEN WHO HAVE SEX WITH MEN IN PLANNING AND POLICY DEVELOPMENT. TAG'S HCV PROGRAM WORKS TO OVERCOME BARRIERS TO HCV PREVENTION AND CARE, INCLUDING LIMITED DONOR FUNDING FOR HCV, RESTRICTIONS IMPOSED BY GOVERNMENTS AND PAYERS, PATENTS, PRICING BARRIERS, INEFFECTIVE VOLUNTARY LICENSING AND DELAYS IN DRUG REGISTRATION BY ORIGINATOR COMPANIES. THE HCV PROGRAM ADVOCATES FOR HARM REDUCTION AND DRUG DECRIMINALIZATION EFFORTS, INCLUDING SUPPORT FOR OVERDOSE PREVENTION AND SAFE CONSUMPTION SITES AS UNSAFE INJECTION DRUG USE IS A MAJOR ROUTE OF HCV TRANSMISSION.IN THE U.S., TAG'S POLICY TEAM WORKS AT THE LOCAL, STATE, AND NATIONAL LEVELS: ADVOCATING FOR VIRAL HEPATITIS FUNDING, CHAMPIONING TREATMENT COVERAGE FOR PEOPLE WHO USE DRUGS, PEOPLE WHO ARE UNSTABLY HOUSED AND INCARCERATED OR OTHERWISE MARGINALIZED PEOPLE, ENCOURAGING VOLUME-BASED PRICING DEALS FOR DAAS, STRENGTHENING NATIONAL SURVEILLANCE, AND SUPPORTING COMMUNITY ENGAGEMENT. TAG'S ADVOCACY HELPED ADVANCE COVERAGE FOR UNIVERSAL ADULT HCV SCREENING AND DRIVE NEW YORK STATE'S COMMITMENT TO ELIMINATE HCV -- THE FIRST IN THE NATION! -- WITH TAG PARTICIPATING IN THE RESULTANT STATEWIDE HCV ELIMINATION TASK FORCE.
Expenses $297,189 · Grants $23,179
-
Expenses $22,387
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Ivy Kwan ArceIVY KWAN ARCE
PRESIDENT
- Total calculated
- $0
- Hours/week
- 4.5
-
Laura MorrisonLAURA MORRISON
TREASURER
- Total calculated
- $0
- Hours/week
- 2.5
-
Mrinal VikramMRINAL VIKRAM
SECRETARY
- Total calculated
- $0
- Hours/week
- 1.5
-
Jim AquinoJIM AQUINO
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Ama BurnhamAMA BURNHAM
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1.5
-
Bob BronzoBOB BRONZO
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Julian ChungJULIAN CHUNG
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Nick DebsNICK DEBS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 0.5
-
Joy EpisallaJOY EPISALLA
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Kevin GoetzKEVIN GOETZ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Dr Stefan GoldbergDR STEFAN GOLDBERG
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1.5
-
Jameel JiwaniJAMEEL JIWANI
DIRECTOR
- Total calculated
- $0
- Hours/week
- 0.5
-
Richard Lynn PhDRICHARD LYNN PHD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 4
-
Robert MonteleoneROBERT MONTELEONE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2.5
-
David PuenteDAVID PUENTE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3.5
-
Karl SchmidKARL SCHMID
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Tanya WalkerTANYA WALKER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 0.5
-
Mark HarringtonMARK HARRINGTON
EXECUTIVE DIRECTOR
- Total calculated
- $212,811
- From this org
- $193,628
- From related orgs
- $0
- Other
- $19,183
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $193,628
- Bonus
- $0
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $19,183
- Filer's total
- $212,811
-
Jason KirkJASON KIRK
CHIEF OPERATING OFFICER
- Total calculated
- $147,367
- From this org
- $128,184
- From related orgs
- $0
- Other
- $19,183
- Hours/week
- 40
-
Lindsay McKennaLINDSAY MCKENNA
TB PROGRAM CO-DIRECTOR
- Total calculated
- $144,223
- From this org
- $125,040
- From related orgs
- $0
- Other
- $19,183
- Hours/week
- 40
-
Mike FrickMIKE FRICK
TB PROGRAM CO-DIRECTOR
- Total calculated
- $144,223
- From this org
- $125,040
- From related orgs
- $0
- Other
- $19,183
- Hours/week
- 40
-
Christopher GeorgeCHRISTOPHER GEORGE
DIRECTOR OF FINANCE
- Total calculated
- $109,180
- From this org
- $109,180
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
-
Elizabeth LovingerELIZABETH LOVINGER
HEALTH POLICY DIRECTOR
- Total calculated
- $159,473
- From this org
- $104,918
- From related orgs
- $0
- Other
- $54,555
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $104,918
- Bonus
- $0
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $54,555
- Filer's total
- $159,473
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
FUNDS PAID OUT AS FISCAL SPONSOR-TB ADVOCACY
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 2 October 2025
- IRS schema version
- 2024v5.2
- Source object
- 202532809349300803
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.